An official statement will be forthcoming, but on 8/2/2022 Abbott provided the following update: The production of our metabolic products has resumed, and we are on track with the timeline communicated during the stakeholder call in July. We anticipate those products to be ready for release in September. You are welcome to share that metabolic formulas have started manufacturing. In the interim, the urgent release process remains in place for patients with urgent needs.